Revolution Medicines

Revolution Medicines is a clinical-stage precision oncology enterprise focused on developing targeted small-molecule inhibitors for patients with RAS-addicted cancers. The enterprise specializes in tri-complex inhibitors that target active RAS mutations in their GTP-bound ON state, including pan-RAS inhibitor RMC-6236 and mutant-selective candidates. By overcoming historical drug discovery barriers surrounding the RAS signaling cascade, Revolution Medicines aims to transform treatment paradigms for pancreatic, lung, and colorectal cancers.